SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Upwind: “By thinking like an adversary the research team stays ahead of the curve”

Anthropic’s $7 billion Decart deal puts a spotlight on its little-known 23-year-old co-founder and chief scientist

You thought you were talking to AI. Police may see a digital diary

The nuclear answer to AI's energy problem is running into the climate crisis

Buzz

Most popular

Daily

Weekly

1

Anthropic closes in on $7 billion Decart deal after beating Nvidia to the table

2

Anthropic’s $7 billion Decart deal puts a spotlight on its little-known 23-year-old co-founder and chief scientist

3

Israel’s GDP is booming. Its domestic economy is telling a different story

4

“Sell everything you have vested”

5

Israel’s academic standing slips as Technion falls out of global top 100

Kare Schultz

6 stories about Kare Schultz

Closure of another criminal case will help Teva's new CEO to focus on return to growth

22.08.23|Sophie Shulman

The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations

ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Schultz kept Teva away from the abyss, but couldn't find a runway to growth

22.11.22|Sophie Shulman

Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines

מפעל טבע טק נאות חובב פיטורים

Teva in talks with Covid-19 vaccine manufacturers to co-produce shots

10.02.21|Reuters and CTech

"We are positive towards contributing by manufacturing some of those vaccines that either have been approved or are just about to be approved," said CEO

קור שולץ מנכ"ל חברת טבע תרופות 23.8.20

Teva beats analysts predictions with increased revenues from growth drivers

10.02.21|Sophie Shulman

The Israeli pharmaceutical company concluded the quarter with $4.5 billion in revenues, bringing it to a total of $16.6 billion for 2020

מנכ"ל טבע החדש קור שולץ

Generic Drugmaker Teva Says Profit Will Continue to Drop in 2018

08.02.18|Dror Reich

Israel’s Teva reports a $17-billion goodwill impairment citing the decline of the U.S. generic market

מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich

Troubled drugmaker says new CEO must work to quickly regain its financial credibility